[Radioactive labeling of cytoplasmic hormone receptors. Determination and clinical significance of estrogen and progesterone receptors].
Neither autoradiography nor in vitro labeling of thin sections of tumor tissue can be used for the quantitative determination of radioactive labeled cytoplasmic hormone receptor. The acknowledged method for his purpose is the DCC (Dextran Coated Charcoal) method. Hormone receptor estimations are routinely used to predict those patients with hormone-dependent tumors who will respond to endocrine therapy. Some 80% of patients with positive estrogen and progesterone receptor show objective remissions after endocrine therapy. Receptor determinations are carried out routinely in patients with mammary, uterine or ovarian carcinoma to identify those subjects who would benefit most from endocrine therapy.
D001943:Breast Neoplasms / Q000032:analysis / Q000000981:diagnostic imaging; D003593:Cytoplasm / Q000032:analysis / Q000000981:diagnostic imaging*; D005260:Female; D005833:Genital Neoplasms, Female / Q000032:analysis / Q000000981:diagnostic imaging; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000032:analysis / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D011960:Receptors, Estrogen / Q000032:analysis*; D011980:Receptors, Progesterone / Q000032:analysis*
D011960:Receptors, Estrogen; D011980:Receptors, Progesterone
Radioaktive Markierung des zytoplasmatischen Hormonrezeptors. Bestimmung und klinische Bedeutung der Ostrogen- und Progesteron-Rezeptoren.